Core Insights - Cosmos Health Inc. is expanding its retail presence in the UK by making its antimicrobial skin cleanser, C-Scrub, available through Superdrug, the second-largest beauty and health retailer in the UK [1][4]. Company Overview - Cosmos Health Inc. is a diversified, vertically integrated global healthcare group established in 2009, with a portfolio of proprietary pharmaceutical and nutraceutical brands [5]. - The company manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices under European Good Manufacturing Practices (GMP) and is certified by the European Medicines Agency (EMA) [5]. - Cosmos Health distributes a wide range of pharmaceuticals and parapharmaceuticals, including branded generics and OTC medications, through subsidiaries in Greece and the UK [5]. Product Details - C-Scrub is a powerful antiseptic wash designed to reduce bacteria and help prevent infection, thereby supporting effective skin hygiene [4]. - The product's availability in Superdrug's extensive retail and pharmacy network enhances Cosmos Health's market positioning in the UK [4]. Strategic Importance - The entry into Superdrug reinforces the retail momentum for C-Scrub in the UK and strengthens the company's market positioning across various retail platforms [5]. - This expansion is expected to increase brand reach and support the long-term development of Cosmos Health's broader product portfolio in the region [5].

Core Insights - Cosmos Health Inc. is expanding its retail presence in the UK by making its antimicrobial skin cleanser, C-Scrub, available through Superdrug, the second-largest beauty and health retailer in the UK [1][4]. Group 1: Company Overview - Cosmos Health Inc. is a diversified, vertically integrated global healthcare group, incorporated in 2009 in Nevada [5]. - The company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including C-Scrub, and operates under European Good Manufacturing Practices (GMP) [5]. - Cosmos Health distributes a wide range of pharmaceuticals and parapharmaceuticals through subsidiaries in Greece and the UK, and has established R&D partnerships targeting major health disorders [5]. Group 2: Product Details - C-Scrub is a powerful antiseptic wash designed to reduce bacteria and help prevent infection, supporting effective skin hygiene [4]. - The product's availability in Superdrug's extensive retail and pharmacy network enhances Cosmos Health's market positioning in the UK [4]. Group 3: Strategic Importance - The entry into Superdrug reinforces the retail momentum for C-Scrub in the UK, significantly strengthening the company's market positioning across various retail platforms [5]. - This expansion increases brand reach and supports the long-term development of Cosmos Health's broader product portfolio in the region [5].

CHICAGO, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced a significant expansion of its United Kingdom (UK) retail footprint as its antimicrobial skin cleanser, C-Scrub Wash Chlorhexidine 4% (“C-Scrub”), is now available through Tesco, the UK’s largest retailer. Tesco is a leading multinational retail group operating across multiple markets and ranked among the top 20 retailer ...

Core Insights - Cosmos Health Inc. participated in the World Health Expo Dubai 2026, one of the largest healthcare exhibitions globally, held from February 9-12, 2026 [1][3] - The event attracted over 235,000 visitors and 4,300 exhibitors from more than 180 countries, facilitating collaboration among healthcare leaders and innovators [3] Company Highlights - Cosmos Health showcased its proprietary nutraceutical and wellness brands, particularly the Sky Premium Life® line, which is gaining traction through expanded distribution and new product introductions [4][6] - The company also highlighted other brands such as C-Scrub®, an antiseptic wash, and Mediterranation®, a luxury nutritional supplement line featuring organic herbs from the Mediterranean [5][6] - The participation at the Expo allowed Cosmos Health to raise awareness of its manufacturing capabilities and engage with potential partners and distributors [6] Strategic Goals - CEO Greg Siok emphasized the company's commitment to expanding its global footprint and strengthening strategic relationships during the Expo [7] - The company is focused on disciplined growth, brand development, and long-term value creation, with ongoing discussions for potential agreements in regions including Japan, China, and Latin America [7] Company Overview - Cosmos Health Inc., incorporated in 2009, is a diversified global healthcare group with a portfolio of proprietary pharmaceutical and nutraceutical brands [8] - The company operates under European Good Manufacturing Practices and is involved in manufacturing pharmaceuticals, food supplements, and medical devices within the EU [8] - Cosmos Health is expanding its distribution across Europe, Asia, and North America, with established offices and distribution centers in Greece and the UK [8]

CHICAGO, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced the expansion of its digital assets program with the purchase of $500,000 of Bitcoin (BTC), underscoring the Company’s disciplined, opportunistic, and flexible approach to capital deployment. The Company’s digital assets program has so far been centered on Ethereum (ETH). While Ethereum will continue to serve as a key pi ...

Core Viewpoint - Cosmos Health Inc. continues to experience operational growth and infrastructure expansion through its subsidiary Cosmofarm, particularly in the pharmaceutical distribution sector in Greece [1]. Group 1: Customer Growth and Financial Performance - In 2025, Cosmofarm added nearly 100 new pharmacy customers, resulting in a 20% increase in its active customer base [2]. - Annual revenue per customer increased by approximately 12%, while profitability per customer improved by around 14%, attributed to enhanced route density and optimized order execution [2]. - Management anticipates that customer growth will continue at similar or higher rates in 2026 based on current onboarding activity and demand trends [2]. Group 2: Infrastructure and Automation Investments - Cosmofarm introduced three new delivery routes in the Attica region to enhance service quality and last-mile delivery performance [3]. - The company has made multi-million dollar investments in automation and logistics infrastructure, including advanced robotic systems for procurement and order fulfillment [4]. - A capital investment program of approximately $1 million is currently underway to expand robotic capacity and throughput [4]. Group 3: Revenue Potential and Operational Efficiency - The expanded ROWA and A-frame robotic picking line is expected to materially increase processing capacity and support an incremental annual revenue potential of approximately $40 million [7]. - The company is upgrading its 29,000-square-foot property in Athens to modernize office space and enhance distribution capabilities [8]. - CEO Greg Siokas emphasized that ongoing investments in automation will significantly expand capacity and support sustainable growth and long-term value creation for Cosmos Health [10].

Core Viewpoint - Cosmos Health Inc. has entered into a manufacturing and supply agreement with Libytec Pharmaceutical S.A. for the production of the pharmaceutical product PathMuscle, enhancing its operational capabilities and revenue visibility in the European market [1][6][7]. Group 1: Agreement Details - The agreement entails Cosmos Health being responsible for the complete manufacturing process of PathMuscle, including formulation, production, quality control, and product release, adhering to regulatory requirements [2]. - The product PathMuscle is a fixed-dose combination of thiocolchicoside and paracetamol, aimed at treating musculoskeletal conditions by providing muscle relaxation and pain relief [3]. - PathMuscle is available in multiple oral presentations, including film-coated tablets and soluble tablets, and is indicated for the treatment of painful muscle spasms associated with acute musculoskeletal disorders [4]. Group 2: Production Volumes - The agreement specifies minimum committed production volumes of 591,500 units, with cumulative production volumes over five years expected to exceed 1.2 million units, depending on market demand [5]. Group 3: Strategic Implications - This agreement reflects Cosmos Health's vertically integrated manufacturing capabilities and is anticipated to improve capacity utilization and enhance revenue visibility across its operations [6]. - The CEO of Cosmos Health emphasized that this collaboration supports the company's strategic focus on expanding pharmaceutical manufacturing through long-term partnerships, showcasing its operational strength and regulatory expertise [7]. Group 4: Company Overview - Cosmos Health Inc. is a diversified global healthcare group, incorporated in 2009, with a portfolio of proprietary pharmaceutical and nutraceutical brands, and operates under European Good Manufacturing Practices [8]. - The company is involved in manufacturing pharmaceuticals, food supplements, and medical devices, and has established R&D partnerships targeting major health disorders, while also expanding its distribution network across Europe, Asia, and North America [8].

Core Insights - Cosmos Health Inc. has seen significant share acquisitions by CEO Greg Siokas, who purchased 301,101 shares between November 19 and November 28, 2025, increasing his total ownership to 6,459,985 shares [1][2][3] - The company reported record-breaking Q3 2025 results, with strong growth across all core business segments, yet its valuation remains under pressure despite these achievements [2][3] Company Overview - Cosmos Health Inc. is a diversified, vertically integrated global healthcare group, incorporated in 2009 in Nevada, owning a portfolio of proprietary pharmaceutical and nutraceutical brands [4] - The company manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices under European Good Manufacturing Practices (GMP) and is certified by the European Medicines Agency (EMA) [4] - Cosmos Health distributes a wide range of pharmaceuticals and parapharmaceuticals through subsidiaries in Greece and the UK, and has established R&D partnerships targeting major health disorders enhanced by artificial intelligence technologies [4] Recent Developments - CEO Greg Siokas has expressed strong confidence in the company's future, stating that he has increased his ownership by over 3 million shares since the beginning of 2025, indicating a commitment to support the company's objectives [2][3] - The company is expanding its global distribution platform throughout Europe, Asia, and North America, with offices and distribution centers in Greece and the UK [4]

Core Insights - Cosmos Health Inc. has initiated a new research and development program utilizing nanotechnology to enhance the effectiveness of phytochemical constituents in dietary supplements [1][2] - The new initiative builds on the proprietary technology developed during the creation of CCX Hydrogel, focusing on plant-based extract-loaded phytosomes to improve absorption, stability, and bioactivity of phytochemicals [2][5] - The company emphasizes a sustainable, solvent-free process for creating phytosomes, aligning with its commitment to environmentally responsible practices [3][5] Company Overview - Cosmos Health Inc. is a diversified, vertically integrated global healthcare group, incorporated in 2009 in Nevada, with a portfolio of proprietary pharmaceutical and nutraceutical brands [6] - The company manufactures a range of products, including pharmaceuticals, food supplements, cosmetics, and medical devices, under European Good Manufacturing Practices (GMP) [6] - Cosmos Health has established R&D partnerships targeting major health disorders and has entered the telehealth space through the acquisition of ZipDoctor, Inc. [6]

Core Insights - Cosmos Health Inc. has acquired an additional $200,000 worth of Ethereum, increasing its total investment in ETH to $2 million [1][2][3] - The acquisition is part of a broader strategy supported by a $300 million digital assets facility aimed at diversifying and strengthening the company's portfolio through targeted digital asset investments [2][3] Company Overview - Cosmos Health Inc. is a diversified, vertically integrated global healthcare group, incorporated in 2009 in Nevada [3] - The company owns a portfolio of proprietary pharmaceutical and nutraceutical brands and operates manufacturing under European Good Manufacturing Practices (GMP) [3] - It distributes a wide range of pharmaceuticals and parapharmaceuticals through subsidiaries in Greece and the UK, and has established R&D partnerships targeting major health disorders [3] - The company has entered the telehealth space through the acquisition of ZipDoctor, Inc. and is expanding its operations globally [3]